On July 20, Genscript Biotech rose 5.6% in regular trading, trading at 14.02 HKD/share, with turnover of approximately HKD 129 million.

On the news front, the company recently showcased its fully automated dark laboratory and deep collaboration with ByteDance in AI-driven drug discovery at the World Artificial Intelligence Conference. ByteDance's protein large language model achieved a wet-lab validation hit rate of up to 82%, with Genscript's TurboCHO high-throughput system serving as the underlying platform. The broader Life Sciences Tools & Services sector also saw a broad rebound, with Wuxi XDC up 7.88%, Insilico up 6.34%, and Wuxi Biologics up 4.81%.

Additionally, selling pressure triggered by CARVYKTI's Q2 net trade sales of approximately USD 657 million — representing only a 10% sequential increase versus Q1's 62% year-over-year growth — had driven the stock to a low of HKD 13.12 on July 17. The current move reflects a technical recovery following that profit-taking episode.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)